In
continuation of my update on Vemurafenib
Longer survival, but also major side effects
The drug approved since February 2012 can be an option for adults
whose melanoma cannot be removed by surgery or has formed secondaries
(metastases) and in whose cancer a change (mutation) has occurred in a certain
gene (BRAF-V600). G-BA had specified the drug dacarbazine as the appropriate
comparator therapy.
In its first AMNOG assessment in June 2012, the Institute
concluded that vemurafenib had major advantages in overall survival, but also
major disadvantages in the form of side effects. Overall, this resulted in an
indication of a considerable added benefit.
No comments:
Post a Comment